Sulfonamides a Promising Hit for Cancer Therapy Through VEGFR-2 Inhibition

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Vascular endothelial growth factor receptor-2 (VEGFR-2) is a key target in anti-angiogenic cancer therapy due to its role in tumor angiogenesis.
• Current VEGFR-2 inhibitors face challenges including drug resistance and cardiac side effects.
• Developing novel therapeutic strategies is crucial to enhance efficacy and minimize adverse events.

Purpose of the Study:

• To review novel compounds with potential VEGFR-2 inhibitory activity.
• To explore multifunctional drugs targeting multiple pathways for improved cancer treatment.
• To highlight sulfonamide derivatives as promising candidates in drug discovery.

Main Methods:

• Literature review of recent studies on VEGFR-2 inhibitors.
• Focus on sulfonamide derivatives with dual inhibitory activities.
• Analysis of compounds targeting VEGFR-2 and carbonic anhydrase.

Main Results:

• Identification of novel compounds with potential VEGFR-2 inhibitory activity.
• Four compounds demonstrated additional carbonic anhydrase inhibitory activity.
• Sulfonamide derivatives offer a versatile scaffold for developing multi-target agents.

Conclusions:

• Novel sulfonamide derivatives represent a promising avenue for developing next-generation anti-angiogenic cancer therapies.
• Multifunctional agents targeting VEGFR-2 and other pathways may overcome resistance and reduce side effects.
• Further research into these compounds could lead to more effective cancer treatments.